Trials
Search / Trial NCT06432101

Acupuncture Combined With Hydroxychloroquine

Launched by SENYUE ZHANG · May 22, 2024

Apply for Trial

Trial Information

Current as of March 14, 2025

Completed

Keywords

ClinConnect Summary

Methods: Seventy-two patients with primary Sjögren's syndrome who met the inclusion criteria were randomly divided into the experimental group (36 patients, 3 patients who fell out) and the control group (36 patients, 4 patients who fell out). The control group was treated with oral hydroxychloroquine sulfate tablets alone, 0.2g each time, taken twice a day, 4 weeks for 1 course of treatment, a total of 2 courses of treatment, and the experimental group was treated with acupuncture treatment on the basis of the control group, acupuncture once a day, acupuncture for 5 days and 2 days of rest...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Clinical diagnosis of primary Sjögren's syndrome
  • • Must be able to receive acupuncture treatment and swallow tablets
  • Exclusion Criteria:
  • • Patients with malignant tumors or severe organ function impairment
  • • Patients who are lactating or pregnant.
  • • Persons who are participating in clinical trials of other drugs.

Trial Officials

Senyue Zhang

Principal Investigator

Heilongjiang University of Chinese Medicine

About Senyue Zhang

Senyue Zhang is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapeutic solutions, Senyue Zhang oversees the design, implementation, and management of clinical trials across various therapeutic areas. Leveraging extensive experience in regulatory compliance and patient engagement, the organization strives to foster collaboration among stakeholders, ensuring the highest standards of safety and efficacy in clinical practice. Through meticulous planning and execution, Senyue Zhang aims to contribute significantly to the development of groundbreaking treatments that address unmet medical needs.

Locations

Harbin, Heilongjiang, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0